Picture EBD Group BIO-Europe Spring 2019 BES Wien Vienna Austria 273x168px
Document › Details

F-Star Biotechnology Ltd.. (4/21/16). "Press Release: F-star to Present at Key Conferences in April and May 2016". Cambridge.

Region Region København (Copenhagen)
  Country Denmark
Organisations Organisation F-Star Biotechnology Ltd.
  Group F-Star (Group)
  Organisation 2 Hume Brophy London
  Group Hume Brophy Communications
Products Product BioEquity Europe 2016 Copenhagen
  Product 2 Boston CEO Conference 2016
Index term Index term F-Star–Informa: investor conference, 201605 supply service F-Star presents at BioEquity Europe 2016
Persons Person Haurum, John (F-Star 201205–201810 CEO before ImClone System + Symphogen LEFT)
  Person 2 Clark, Mary (Optimum Strategic Communications 201710 before Hume Brophy + M:Communications + Capital MSL)

F-star, a biopharmaceutical company developing novel bispecific antibodies with a focus on immuno-oncology, today announced presentations at the following events:

(1) PEGS Boston
25 – 29 April 2016, Seaport World Trade Center, Boston, USA

John Haurum, Chief Executive Officer, to chair, on Tuesday 26th April at 10:50 am ET, the session
entitled: ‘From the immuno-oncology trenches: Preclinical Monotherapy, Antibody Combination
and Bispecific Antibody Approaches’

Neil Brewis, Chief Scientific Officer, to present on Tuesday 26th April at 2:35 pm ET

Attracting over 2,000 participants this year, PEGS Summit Boston provides a forum for collaborating and sharing best practices in the areas of protein and antibody engineering, expression, analytical, immunogenicity, as well as oncology and therapeutics. There will be presentations delivering new unpublished data, case studies, innovation and insight. With 100 exhibiting companies and over 200 research posters on display, the event will provide valuable viewing of innovative new technologies, as well as networking with biopharma researchers and industry representatives.

(2) Bio€quity Europe
10 – 11 May 2016, Scandic Hotel, Copenhagen, Denmark

John Haurum, Chief Executive Officer, to present on Tuesday 10th May at 4:00 pm CET

Now in its 17th year, Bio€quity Europe is a major industry event for financial dealmakers looking for investor-validated life science companies, and for pharmaceutical licensing professionals to assess top prospects. Bio€quity Europe has showcased more than 700 leading European companies to thousands of investment and pharma business development professionals. Delegates from over 20 nations attended Bio€quity Europe last year.

(3) Advances in Immuno-oncology Congress
12 – 13 May 2016, Wrights Lane Kensington, London, UK

Jaqueline Doody, Vice President, Immunology, to present on Friday 13th May at 2.30 pm BST

The inaugural Advances in Immuno-oncology Congress will feature a panel of leading global experts in the field of cancer immunotherapy addressing the main challenges and opportunities in the industry, including the latest advances in therapeutic approaches, clinical trial data, and collaborations. Speakers will discuss innovations in areas including the moving beyond the PD-1 pathway, humanised mouse models, bispecific antibodies, CAR T therapy, cancer vaccines and combination therapies.

(4) Boston CEO Conference
31 May – 1 June 2016, Four Seasons Boston, Boston, USA

John Haurum, Chief Executive Officer, to join the panel on Tuesday 31st May at 3.00 pm ET entitled: ‘Oncology Trends and Predictions’

The Boston CEO Conference is a networking forum for industry CEOs and decision makers in the life sciences. Attendees gain insights from presentations and panels featuring CEOs from several of the world's leading biopharmaceutical companies. Industry leaders in venture capital and private equity also participate.


For further information, please contact:

John Haurum
Chief Executive Officer
+ 44 7881 244 040

Jane Dancer
Chief Business Officer
+ 44 7739 174 297

Hume Brophy
Mary Clark, Eva Haas, Alexia Faure
+44 207 862 6381

About F-star

F-star is a clinical-stage biopharmaceutical company developing bispecific antibody immuno-oncology products selected for their potential to transform the treatment of cancer. Through the application of its highly efficient Modular Antibody Technology™ platform, F-star is the only biotechnology company able to create bispecific antibodies where the second binding site is in the constant Fc region of an antibody. The strength of the technology and programmes has been leveraged through partnerships with leading biopharmaceutical companies including AbbVie, Bristol-Myers Squibb, Merck Serono and Boehringer Ingelheim. F-star has currently one program in the clinic with a second immuno-oncology program heading toward IND. The Company has built a comprehensive IP estate around its technology and product pipeline, with over 50 patent applications filed and over 25 granted patents.

F-star’s management team has a well-established track record in building successful biotech companies, and developing biologics. The team is advised by a world-leading scientific advisory board and a highly experienced board of directors. F-star has raised close to $100M in non-dilutive capital and revenues. The company currently employs over 60 people at its research site in Cambridge, UK.

For more information visit

Record changed: 2017-07-02


Picture EBD Group BIO-Europe Spring 2019 BES Wien Vienna Austria 273x168px

More documents for F-Star (Group)

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]


Picture [LSUS] – The Business Web Portal 600x60px

» top